Xtandi 40 MG tablet 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FJXF8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,255
Award facts
- Contract value 100% obligated
- $4,255.34 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $4,255.34 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of 120 tablets of Xtandi 40 mg. The award, issued on January 27, 2026, with an ultimate completion date of January 28, 2026, represents a firm fixed-price delivery order with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to supply pharmaceutical products to Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has maintained consistent federal contracting performance since its registration in the System for Award Management in 2001, demonstrating substantial capability across diverse pharmaceutical categories including oncology treatments, biologics, vaccines, and specialty pharmaceuticals. The company serves as a critical supplier within the federal pharmaceutical supply chain, leveraging its small business status to compete effectively in government procurement. Under the PPV-G GEN V contract framework, which runs through December 31, 2036, DMS Pharmaceutical Group is positioned to fulfill recurring medical supply needs for military healthcare operations globally, with delivery orders ranging from nominal purchases to awards exceeding $115,000.
Quick answers
Who was awarded contract SPE2DR26FJXF8?
SPE2DR26FJXF8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FJXF8 worth?
The government has obligated $4,255 on SPE2DR26FJXF8.
Is contract SPE2DR26FJXF8 an order under another contract?
Yes. SPE2DR26FJXF8 is a delivery order under SPE2DR25D9307, an indefinite delivery contract.
Was contract SPE2DR26FJXF8 competed?
The extent of competition for SPE2DR26FJXF8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award